SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

Tomasz Rzymski; Michał Mikula; Eliza Żyłkiewicz; Agnieszka Dreas; Katarzyna Wiklik; Aniela Gołas; Katarzyna Wójcik; Magdalena Masiejczyk; Anna Wróbel; Izabela Dolata; Agata Kitlińska; Małgorzata Statkiewicz; Urszula Kuklinska; Krzysztof Goryca; Łukasz Sapała; Aleksandra Grochowska; Aleksandra Cabaj; Małgorzata Szajewska-Skuta; Ewelina Gabor-Worwa; Katarzyna Kucwaj; Arkadiusz Białas; Adam Radzimierski; Michał Combik; Jakub Woyciechowski; Maciej Mikulski; Renata Windak; Jerzy Ostrowski; Krzysztof Brzózka

doi:10.18632/oncotarget.16810

journal article Apr 04, 2017

SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

Tomasz Rzymski Michał Mikula Eliza Żyłkiewicz Agnieszka Dreas Katarzyna Wiklik Aniela Gołas Katarzyna Wójcik Magdalena Masiejczyk Anna Wróbel Izabela Dolata Agata Kitlińska Małgorzata Statkiewicz Urszula Kuklinska Krzysztof Goryca Łukasz Sapała Aleksandra Grochowska Aleksandra Cabaj Małgorzata Szajewska-Skuta Ewelina Gabor-Worwa Katarzyna Kucwaj Arkadiusz Białas Adam Radzimierski Michał Combik Jakub Woyciechowski Maciej Mikulski

Renata Windak Jerzy Ostrowski

Krzysztof Brzózka

Oncotarget Vol. 8 No. 20 pp. 33779-33795 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.16810

Topics

No keywords indexed for this article. Browse by subject →

References

57

[1]

The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function

Matthew T. Knuesel, Krista D. Meyer, Carrie Bernecky et al.

Genes & Development 2009 10.1101/gad.1767009

[2]

Brzózka "CDK8 kinase — An emerging target in targeted cancer therapy" Biochim Biophys Acta (2015) 10.1016/j.bbapap.2015.05.011

[3]

Nicolaou "Cortistatin a is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11" Angew Chemie Int Ed (2009) 10.1002/anie.200904778

[4]

Mediator kinase inhibition further activates super-enhancer-associated genes in AML

Henry E. Pelish, Brian B. Liau, Ioana I. Nitulescu et al.

Nature 2015 10.1038/nature14904

[5]

Schneider "Potent, specific CDK8 kinase inhibitors lack CDK8-dependent antiproliferative activity in HCT-116 colon cancer cell line" ACS Med Chem Lett (2016) 10.1021/acsmedchemlett.5b00278

[6]

Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics

Zachary C. Poss, Christopher C. Ebmeier, Aaron T. Odell et al.

Cell Reports 2016 10.1016/j.celrep.2016.03.030

[7]

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

Ron Firestein, Adam J. Bass, So Young Kim et al.

Nature 2008 10.1038/nature07179

[8]

CDK8 is a positive regulator of transcriptional elongation within the serum response network

Aaron J Donner, Christopher C Ebmeier, Dylan J Taatjes et al.

Nature Structural & Molecular Biology 2010 10.1038/nsmb.1752

[9]

Espinosa "CDK8 is a stimulus-specific positive coregulator of p53 target genes" Mol Cell (2007) 10.1016/j.molcel.2007.05.026

[10]

Kalurupalle "Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities" Proc Natl Acad Sci U S A (2012) 10.1073/pnas.1206906109

[11]

Jones "Mastermind recruits CycC: CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover" Mol Cell (2004) 10.1016/j.molcel.2004.10.014

[12]

Espinosa "HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia" Cell (2013) 10.1016/j.cell.2013.04.048

[13]

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

Aurélie Mallinger, Kai Schiemann, Christian Rink et al.

Journal of Medicinal Chemistry 2016 10.1021/acs.jmedchem.5b01685

[14]

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease

Trevor Dale, Paul A Clarke, Christina Esdar et al.

Nature Methods 2015 10.1038/nchembio.1952

[15]

Espinosa "CDK8: a positive regulator of transcription" Transcription (2010) 10.4161/trns.1.1.12373

[16]

Demma "CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation" Oncogene (2013) 10.1038/onc.2012.364

[17]

Kovarik "CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response" Immunity (2013) 10.1016/j.immuni.2012.10.017

[18]

TFIIH is negatively regulated by cdk8-containing mediator complexes

Sasha Akoulitchev, Sergei Chuikov, Danny Reinberg

Nature 2000 10.1038/35024111

[19]

The Protein Data Bank archive as an open data resource

Helen M. Berman, Gerard J. Kleywegt, Haruki Nakamura et al.

Journal of Computer-Aided Molecular Design 2014 10.1007/s10822-014-9770-y

[20]

Porter, Liang, Kaza, Chumanevich, Altilia, Farmaki, Chen, Schools, Chatzistamou, Pena, Friedhoff, Wentland, Broude, et al. Targeting the seed and the soil of cancers with selective small-molecule inhibitors of CDK8/19: Chemopotentiating, chemopreventive, anti-invasive and anti-metastatic activities. AACR Annual Meeting, 2014 April 5-9, 2014. San Diego, CA. 2014. 10.1158/1538-7445.am2014-4879

[21]

Hobbs "Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen" J Med Chem (2015) 10.1021/jm501436m

[22]

Structure–kinetic relationship study of CDK8/CycC specific compounds

Elisabeth V. Schneider, Jark Böttcher, Robert Huber et al.

Proceedings of the National Academy of Sciences 2013 10.1073/pnas.1305378110

[23]

Darnell "Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation" Cell (1995) 10.1016/0092-8674(95)90311-9

[24]

Price "Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo" J Biol Chem (2001) 10.1074/jbc.m102306200

[25]

Johnson "The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation" EMBO J (2008) 10.1038/emboj.2008.121

[26]

Arima "Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles" Leukemia (2000) 10.1038/sj.leu.2401608

[27]

Segal "A module of negative feedback regulators defines growth factor signaling" Nat Genet (2007) 10.1038/ng1987

[28]

Augenlicht "Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression" J Biol Chem (2003) 10.1074/jbc.m304721200

[29]

Domany "Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer" Oncogene (2005) 10.1038/sj.onc.1208797

[30]

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Aravind Subramanian, Pablo Tamayo, Vamsi K. Mootha et al.

Proceedings of the National Academy of Sciences 2005 10.1073/pnas.0506580102

[31]

Lawrence "The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells" Blood (2004) 10.1182/blood-2003-07-2202

[32]

Sauvageau "Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b" EMBO J (1998) 10.1093/emboj/17.13.3714

[33]

Zeng "Identification and characterization of Hoxa9 binding sites in hematopoietic cells" Blood (2012) 10.1182/blood-2011-03-341081

[34]

Sauvageau "Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion" Blood (2002) 10.1182/blood.v99.1.121

[35]

Hewitt "Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases" Elife (2016) 10.7554/elife.20722

[36]

Kreft "STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2" Cancer Res (2013) 10.1158/0008-5472.can-12-0255

[37]

Grant "Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)" Leuk Res Reports (2013) 10.1016/j.lrr.2012.11.006

[38]

Murray "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity" Nature (2012) 10.1038/nature11003

[39]

Segal "Identifying differentially expressed genes from microarray experiments via statistic synthesis" Bioinformatics (2005) 10.1093/bioinformatics/bti108

[40]

Schrader "Production of interleukin 1beta by human hematopoietic progenitor cells" J Clin Invest (1996) 10.1172/jci118593

[41]

Lemischka "A stem cell molecular signature" Science (2002) 10.1126/science.1073823

[42]

Asou "Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML" Blood (2009) 10.1182/blood-2009-02-204818

[43]

Borowitz "A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia" Blood (2012) 10.1182/blood-2011-06-364182

[44]

Ivey "Genetically distinct leukemic stem cells in human CD34 − acute myeloid leukemia are arrested at a hemopoietic precursor-like stage" J Exp Med (2016) 10.1084/jem.20151775

[45]

Strobl "The good and the bad faces of STAT1 in solid tumours" Cytokine (2015) 10.1016/j.cyto.2015.11.011

[46]

Pawitan "An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer" Proc Natl Acad Sci U S A (2008) 10.1073/pnas.0809242105

[47]

Weichselbaum "Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth" Clin Cancer Res (2012) 10.1158/1078-0432.ccr-11-3225

[48]

The consensus molecular subtypes of colorectal cancer

Justin Guinney, Rodrigo Dienstmann, Xin Wang et al.

Nature Medicine 2015 10.1038/nm.3967

[49]

Müller "CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance" Cell Rep (2013) 10.1016/j.celrep.2013.07.012

[50]

Vellenga "STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells" Blood (2007) 10.1182/blood-2006-08-039073

Showing 50 of 57 references

Cited By

98

Clinical development of a CDK8/19 kinase inhibitor for acute myeloid leukemia

Akhil Rajendra, Karen W. L. Yee · 2026

Expert Opinion on Investigational D...

Cyclin C promotes pancreatic developmentand suppresses cancer initiation by maintenance of the autophagy-lysosome pathway

Sara E. Hanley, Kathy Q. Cai · 2026

iScience

Drugging non-canonical kinases in cancer therapeutics: Molecular targets, underlying mechanisms and small-molecule inhibitors

Xuelan Ma, Zhifeng Wen · 2026

Acta Pharmaceutica Sinica B

From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy

Zhenfeng Shi, Lei Tian · 2022

Journal of Medicinal Chemistry

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Li Zhang, Chen Cheng · 2022

Journal of Medicinal Chemistry

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

Jen-Chieh Lee, Shu Liu · 2022

Oncotarget

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review

Paweł Łukasik, Michał Załuski · 2021

International Journal of Molecular...

Targeting transcription cycles in cancer

Stephin J. Vervoort, Jennifer R. Devlin · 2021

Nature Reviews Cancer

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

Marco H. Hofmann, Rajeswaran Mani · 2020

Molecular Cancer Therapeutics

Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition

Mengqian Chen, Jing Li · 2019

Cells

Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay

Jing Li, Hao Ji · 2019

Cells

Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T reg cells by inhibition of CDK8/19

Masahiko Akamatsu, Norihisa Mikami · 2019

Science Immunology

NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses

Agnieszka Witalisz-Siepracka, Dagmar Gotthardt · 2018

Cancer Immunology Research

CDK8/19 Mediator kinases potentiate induction of transcription by NFκB

Mengqian Chen, Jiaxin Liang · 2017

Proceedings of the National Academy...

Metrics

98

Citations

57

References

Details

Published: Apr 04, 2017
Vol/Issue: 8(20)
Pages: 33779-33795

Authors

T

Tomasz Rzymski

R&D Department, Selvita S.A., Kraków, Poland

M

Michał Mikula

Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

E

Eliza Żyłkiewicz

R&D Department, Selvita S.A., Kraków, Poland

A

Agnieszka Dreas

R&D Department, Selvita S.A., Kraków, Poland

K

Katarzyna Wiklik

R&D Department, Selvita S.A., Kraków, Poland

A

Aniela Gołas

R&D Department, Selvita S.A., Kraków, Poland

K

Katarzyna Wójcik

R&D Department, Selvita S.A., Kraków, Poland

M

Magdalena Masiejczyk

R&D Department, Selvita S.A., Kraków, Poland

A

Anna Wróbel

R&D Department, Selvita S.A., Kraków, Poland

I

Izabela Dolata

R&D Department, Selvita S.A., Kraków, Poland

A

Agata Kitlińska

R&D Department, Selvita S.A., Kraków, Poland

M

Małgorzata Statkiewicz

Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

U

Urszula Kuklinska

Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

K

Krzysztof Goryca

Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

�

Łukasz Sapała

Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland

A

Aleksandra Grochowska

Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland

A

Aleksandra Cabaj

Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland; Laboratory of Bioinformatics, Nencki Institute of Experimental Biology, Warsaw, Poland

M

Małgorzata Szajewska-Skuta

R&D Department, Selvita S.A., Kraków, Poland

E

Ewelina Gabor-Worwa

R&D Department, Selvita S.A., Kraków, Poland

K

Katarzyna Kucwaj

R&D Department, Selvita S.A., Kraków, Poland

A

Arkadiusz Białas

R&D Department, Selvita S.A., Kraków, Poland

A

Adam Radzimierski

R&D Department, Selvita S.A., Kraków, Poland

M

Michał Combik

R&D Department, Selvita S.A., Kraków, Poland

J

Jakub Woyciechowski

R&D Department, Selvita S.A., Kraków, Poland

M

Maciej Mikulski

R&D Department, Selvita S.A., Kraków, Poland

R

Renata Windak

R&D Department, Selvita S.A., Kraków, Poland

J

Jerzy Ostrowski

Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland; Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland

K

Krzysztof Brzózka

R&D Department, Selvita S.A., Kraków, Poland

Cite This Article

Tomasz Rzymski, Michał Mikula, Eliza Żyłkiewicz, et al. (2017). SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget, 8(20), 33779-33795. https://doi.org/10.18632/oncotarget.16810

SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

You May Also Like